Pros and cons for C4d as a biomarker
Daniëlle Cohen(Royal Hallamshire Hospital), Ingeborg M. Bajema(University Medical Center Groningen), B. Sis(The Metabolomics Innovation Centre), Cinthia B. Drachenberg(University of Maryland, Baltimore), Mohamed R. Daha(University of Groningen), Mark Haas(Cedars-Sinai Medical Center), Jane E. Salmon(Hospital for Special Surgery), Jan A. Bruijn(Leiden University Medical Center), Volker Nickeleit(University of North Carolina at Chapel Hill), Ming Zhao(Beijing Forestry University), Robert B. Colvin(Harvard University)
Cited by 210
Related Papers
The Banff 97 working classification of renal allograft pathology
|Kidney International|1999|3.1k
Banff 07 Classification of Renal Allograft Pathology: Updates and Future Directions
|American Journal of Transplantation|2008|1.9k
Reactivity of a monoclonal antibody with human ovarian carcinoma.
|Journal of Clinical Investigation|1981|1.7k
International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology
|Kidney International|1993|1.5k
Banff 2013 Meeting Report: Inclusion of C4d-Negative Antibody-Mediated Rejection and Antibody-Associated Arterial Lesions
|American Journal of Transplantation|2014|1.3k